Search


	Podcast:		BioCentury This Week
	Episode:		Bonus Content - Trends in Global Biopharma Deals: Lazard’s Kingston and Raine
	Category:		Science & Medicine
	Duration:		00:34:54
	Publish Date:		2024-12-23 20:00:00
	Description:		With most of the highly attractive late-stage assets already scooped up, pharmas are turning their sights to Phase II companies, and lining up their case to make an attractive offer and move fast. About 40% of the M&A deals in 2023-24 were completed in less than six weeks, from approach to announcement, according to Lazard’s data. Michael Kingston and Dale Raine, global co-heads of biopharma at Lazard, joined The BioCentury Show this week to discuss the M&A outlook amid the still-precarious biotech financing landscape. The BioCentury Show, featuring BioCentury one-on-one with an industry KOL, is available on Apple, Spotify and wherever you listen to your favorite podcasts and in video podcast format on BioCentury’s YouTube channel. View full story: https://www.biocentury.com/article/653858 00:00 - Introduction 03:01 - Capital Markets Outlook 06:01 - M&A 15:19 - Breaking Down Deals 24:29 - Asia To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text
	Total Play:		0